| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5671670 | Clinical Microbiology and Infection | 2017 | 31 Pages |
Abstract
Tenofovir and entecavir have similar effectiveness in NA-naive CHB patients with high viraemia. Tenofovir might have a higher incidence of acute kidney injury compared with entecavir during treatment.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
I.-T. Wu, T.-H. Hu, C.-H. Hung, S.-N. Lu, J.-H. Wang, C.-M. Lee, C.-H. Chen,